LanzaTech and Plastipak produce greener PET
Carbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions.
Roches meets endpoints in relapsing multiple sclerosis
Roche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.
Dualyx NV raises 40m in Series A financing
Belgian T reg specialist Dualyx NV had raised 40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
Sanofi’s/Astazeneca’s anti-RSV antibody highly effective
NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.
Mainz Biomed Partners with Microba Life Sciences
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
DiogenX SA raises 27.5M in Series A financing
French pancreatic beta-cell modulator specialist DiogenX SA has raised 27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Wacker AG expands biotech business through 100m acquisition
Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for 100m.
Neogap Therapeutics A/S partners with Cellerys AG
Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Dutch State to sell share capital of Intravacc BV
The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.